Recently Alamar Biosciences, the Alzheimer’s Disease Data Initiative (ADDI), and Gates Ventures announced a new strategic partnership aimed at creating one of the largest datasets of proteomic and clinical data for Alzheimer’s disease. The international project will profile over 40,000 plasma samples from individuals with Alzheimer’s and related dementias. This ambitious effort aims to accelerate the discovery of new biomarkers and provide deeper insights into how Alzheimer’s progresses and how it can be treated.

Damian Doherty, Inside Precision Medicine’ s Editor in Chief, spoke to the CEO of Alamar Biosciences, Yuling Luo, PhD, and Niranjan Bose, PhD, Managing Director of Health & Life Sciences at Gates Ventures and interim Executive Director of the Alzheimer’s Disease Data Initiative

See Full Page